CL2016001024A1 - Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. - Google Patents

Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.

Info

Publication number
CL2016001024A1
CL2016001024A1 CL2016001024A CL2016001024A CL2016001024A1 CL 2016001024 A1 CL2016001024 A1 CL 2016001024A1 CL 2016001024 A CL2016001024 A CL 2016001024A CL 2016001024 A CL2016001024 A CL 2016001024A CL 2016001024 A1 CL2016001024 A1 CL 2016001024A1
Authority
CL
Chile
Prior art keywords
schizophrenia
depression
diseases
treatment
pharmaceutical composition
Prior art date
Application number
CL2016001024A
Other languages
English (en)
Inventor
Jens-Uwe Peters
Ravi Jagasia
Roland Jakob-Roetne
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2016001024A1 publication Critical patent/CL2016001024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

COMPUESTOS DERIVADOS DE PIRIDO[4,3-B]PIRAZÍN-2-CARBOXAMIDAS; PROCEDIMIENTO DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA Y USO PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS, ESQUIZOFRENIA, DEPRESIÓN, ENTRE OTRAS ENFERMEDADES.
CL2016001024A 2013-11-12 2016-04-29 Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. CL2016001024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192406 2013-11-12

Publications (1)

Publication Number Publication Date
CL2016001024A1 true CL2016001024A1 (es) 2016-11-18

Family

ID=49552255

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001024A CL2016001024A1 (es) 2013-11-12 2016-04-29 Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.

Country Status (17)

Country Link
US (1) US9670206B2 (es)
EP (1) EP3068781B1 (es)
JP (1) JP6229056B2 (es)
KR (1) KR101861937B1 (es)
CN (1) CN105764901B (es)
AU (1) AU2014350371B2 (es)
CA (1) CA2929461A1 (es)
CL (1) CL2016001024A1 (es)
CR (1) CR20160142A (es)
EA (1) EA028940B1 (es)
IL (1) IL244619A0 (es)
MA (1) MA39027B1 (es)
MX (1) MX2016006052A (es)
PE (1) PE20160692A1 (es)
PH (1) PH12016500605A1 (es)
UA (1) UA117041C2 (es)
WO (1) WO2015071178A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018500877B1 (en) 2015-10-26 2023-09-20 Bayer Cropscience Ag Condensed bicyclic heterocycle derivatives as pest control agents
KR20210040085A (ko) * 2018-07-31 2021-04-12 메르크 파텐트 게엠베하 Tlr7/8 안타고니스트 및 이의 용도
BR112021010400A2 (pt) 2019-02-26 2021-08-24 Bayer Aktiengesellschaft Derivados heterocíclicos bicíclicos condensados como agentes de controle de praga
US20230060425A1 (en) 2019-02-26 2023-03-02 Bayer Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773834A2 (en) * 2004-08-03 2007-04-18 Serenex, Inc. 2, 8-disubstituted naphthyridine derivatives
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
CN102414180A (zh) * 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
CA2759547A1 (en) * 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2012006419A2 (en) * 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
EP2991635B1 (en) * 2013-05-03 2017-04-12 F. Hoffmann-La Roche AG Neurogenesis-stimulating isoquinoline derivatives
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物

Also Published As

Publication number Publication date
HK1223916A1 (zh) 2017-08-11
EA028940B1 (ru) 2018-01-31
JP6229056B2 (ja) 2017-11-08
MX2016006052A (es) 2016-07-18
IL244619A0 (en) 2016-04-21
UA117041C2 (uk) 2018-06-11
KR20160061427A (ko) 2016-05-31
KR101861937B1 (ko) 2018-05-28
CN105764901B (zh) 2018-06-22
EP3068781B1 (en) 2017-12-20
PE20160692A1 (es) 2016-07-28
CA2929461A1 (en) 2015-05-21
AU2014350371B2 (en) 2018-02-15
US9670206B2 (en) 2017-06-06
CR20160142A (es) 2016-05-04
MA39027A1 (fr) 2018-05-31
CN105764901A (zh) 2016-07-13
WO2015071178A1 (en) 2015-05-21
PH12016500605A1 (en) 2016-06-13
EA201690971A1 (ru) 2016-08-31
JP2016536320A (ja) 2016-11-24
EP3068781A1 (en) 2016-09-21
US20160251355A1 (en) 2016-09-01
MA39027B1 (fr) 2018-10-31

Similar Documents

Publication Publication Date Title
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2014002412A1 (es) Compuestos derivados de pirido[4,3-d]pirimidina, como inhibidores de mek; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades inflamatorias, infecciones, trastornos autoinmunes, enfermedades metabolicas y enfermedades malignas, entre otras.
CL2016001895A1 (es) Compuestos
CL2017001930A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
MX2015003140A (es) Formulaciones de enzalutamida.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
HUE064667T2 (hu) Pirido[3',4':4,5]pirrolo[1,2,3-de]kinoxalin származékok központi idegrendszeri betegségek kezelésében történõ alkalmazásra
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2013003052A1 (es) Compuestos derivados de 2h-pirazol[3,4-c]-quinolina, 2h-pirazol[3,4-c][1,5 o 1,7]-naftiridina y 2h-benzo[b][1,4]-oxazina, sus composiciones farmaceuticas utiles para el tratamiento de enfermedades y trastornos del aparato respiratorio, anafilaxia sistemica o respuestas de hipersensibilidad entre otras.
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
MX392130B (es) Derivados de pirrolo[3,2-d]pirimidina para el tratamiento de infecciones víricas y otras enfermedades.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
MX2018015734A (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1.
PH12014501991B1 (en) Phenicol antibacterials